Article
Sanofi Ends Development of Two Phase III Drugs
Author(s):
-
Sanofi has discontinueddevelopment of two investigational drugs in Phase III development, iniparib, a drug to treat non-small cell lung cancer, and otamixaban, an anticoagulant, based on recent clinical results. Sanofi will take an after-tax change of $285 million for iniparib.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Videos
Related Content
